A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520554-11-00

Acronym

20230222

Enrollment

3800

Registered

2025-09-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Brief summary

Time to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs first

Detailed description

Time to cardiovascular death, myocardial infarction, or ischemic stroke, whichever occurs first, Time to cardiovascular death, myocardial infarction, urgent coronary revascularization, or ischemic stroke, whichever occurs first, Percent change from baseline to week 48 Lp(a) levels

Interventions

DRUGPlacebo for AMG 890

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs first	—

Secondary

Measure	Time frame
Time to cardiovascular death, myocardial infarction, or ischemic stroke, whichever occurs first, Time to cardiovascular death, myocardial infarction, urgent coronary revascularization, or ischemic stroke, whichever occurs first, Percent change from baseline to week 48 Lp(a) levels	—

Countries

Austria, Belgium, Bulgaria, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Poland, Portugal, Romania, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026